Literature DB >> 22909078

Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria.

I Weitz1, G Meyers, T Lamy, J-Y Cahn, M T Uranga, J A García Vela, M A Sanz, B Severino, R J Kelly, P Hillmen, A Hill.   

Abstract

BACKGROUND: Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired, clonal haemopoietic stem cell disorder that causes chronic intravascular haemolysis, increases the risk of thrombosis and results in significant patient morbidity and mortality. The symptoms of PNH may have a major impact on patient quality of life. AIMS: To assess patient fatigue and health-related quality of life in 29 patients with PNH using the Functional Assessment of Chronic Illness Therapy Fatigue subscale version 4 (FACIT-Fatigue) and the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-C30, version 3 (EORTC QLQ-C30).
METHODS: Following completion of the questionnaires, patients were interviewed to assess the validity, clarity, relevance and comprehensiveness of the assessments.
RESULTS: Overall, patients considered both the FACIT-Fatigue and EORTC QLQ-C30 instruments to be relevant and adequate in assessing the level of PNH-associated fatigue and other quality-of-life measures. The FACIT-Fatigue questionnaire was considered to be clear and to comprehensively cover PNH-related fatigue. The EORTC QLQ-C30 instrument was considered to be easy to understand, but of an overall lower relevance, although some differences between countries were observed. Patients suggested additional questions that could be incorporated into future EORTC QLQ-C30 versions to make it more relevant to PNH.
CONCLUSIONS: This study confirms the validity of the FACIT-Fatigue and the EORTC QLQ-C30 questionnaires in this patient population and their routine use should be considered in the management of patients with PNH.
© 2012 The Authors; Internal Medicine Journal © 2012 Royal Australasian College of Physicians.

Entities:  

Mesh:

Year:  2013        PMID: 22909078     DOI: 10.1111/j.1445-5994.2012.02924.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  10 in total

1.  Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.

Authors:  Haruhiko Ninomiya; Naoshi Obara; Shigeru Chiba; Kensuke Usuki; Kaichi Nishiwaki; Itaru Matsumura; Tsutomu Shichishima; Shinichiro Okamoto; Jun-Ichi Nishimura; Kazuma Ohyashiki; Shinji Nakao; Kiyoshi Ando; Yoshinobu Kanda; Tatsuya Kawaguchi; Hideki Nakakuma; Daisuke Harada; Hirozumi Akiyama; Taroh Kinoshita; Keiya Ozawa; Mitsuhiro Omine; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2016-07-27       Impact factor: 2.490

Review 2.  Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bed.

Authors:  Amrallah A Mohammed; Hani El-Tanni; Tariq Al-Malki Atiah; Arwa Al-Malki Atiah; Marwan Al-Malki Atiah; Ayman A Rasmy
Journal:  Indian J Hematol Blood Transfus       Date:  2016-02-12       Impact factor: 0.900

3.  Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies.

Authors:  Alexander Röth; Scott T Rottinghaus; Anita Hill; Eric S Bachman; Jin Seok Kim; Hubert Schrezenmeier; Louis Terriou; Álvaro Urbano-Ispizua; Richard A Wells; Jun Ho Jang; Austin G Kulasekararaj; Jeff Szer; Rasha Aguzzi; Andrew I Damokosh; Lori Shafner; Jong Wook Lee
Journal:  Blood Adv       Date:  2018-09-11

Review 4.  Paroxysmal nocturnal haemoglobinuria.

Authors:  Anita Hill; Amy E DeZern; Taroh Kinoshita; Robert A Brodsky
Journal:  Nat Rev Dis Primers       Date:  2017-05-18       Impact factor: 52.329

5.  Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan.

Authors:  Yasutaka Ueda; Naoshi Obara; Yuji Yonemura; Hideyoshi Noji; Masayoshi Masuko; Yoshinobu Seki; Katsuya Wada; Takahisa Matsuda; Hirozumi Akiyama; Takayuki Ikezoe; Shigeru Chiba; Yoshinobu Kanda; Tatsuya Kawaguchi; Tsutomu Shichishima; Hideki Nakakuma; Shinichiro Okamoto; Jun-Ichi Nishimura; Yuzuru Kanakura; Haruhiko Ninomiya
Journal:  Int J Hematol       Date:  2018-01-30       Impact factor: 2.490

6.  The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.

Authors:  David Dingli; Joana E Matos; Kerri Lehrhaupt; Sangeeta Krishnan; Michael Yeh; Jesse Fishman; Sujata P Sarda; Scott B Baver
Journal:  Ann Hematol       Date:  2022-01-01       Impact factor: 3.673

Review 7.  Literature Review of Fatigue Scales and Association with Clinically Meaningful Improvements in Outcomes Among Patients With and Without Paroxysmal Nocturnal Hemoglobinuria.

Authors:  Sangeeta Krishnan; Sujata Sarda; Colin Kunzweiler; Melody Wu; Sanjana Sundaresan; Lynn Huynh; Mei Sheng Duh; Carmelita P Escalante
Journal:  Adv Ther       Date:  2022-03-22       Impact factor: 4.070

8.  The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient-reported insights on symptoms and quality of life.

Authors:  Jens Panse; Flore Sicre de Fontbrune; Pascale Burmester; Maria Piggin; Joana E Matos; Halley Costantino; Koo Wilson; Zalmai Hakimi; Jameel Nazir; Renaud Desgraz; Jesse Fishman; Emmelie Persson; Austin Kulasekararaj
Journal:  Eur J Haematol       Date:  2022-07-07       Impact factor: 3.674

9.  Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry.

Authors:  Jun Ho Jang; Jin Seok Kim; Sung-Soo Yoon; Je-Hwan Lee; Yeo-Kyeoung Kim; Deog-Yeon Jo; Jooseop Chung; Sang Kyun Sohn; Jong Wook Lee
Journal:  J Korean Med Sci       Date:  2016-01-26       Impact factor: 2.153

10.  Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Austin Kulasekararaj; Axel Glasmacher; Peng Liu; Jeff Szer; David Araten; Geraldine Rauch; Chad Gwaltney; J Rafael Sierra; Jong Wook Lee
Journal:  Eur J Haematol       Date:  2022-03-01       Impact factor: 3.674

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.